Literature DB >> 19200863

The history of multiple sclerosis: the changing frame of the disease over the centuries.

T Jock Murray1.   

Abstract

For centuries, it was recognised that there was a condition characterised by episodic and progressive neurological deterioration, classified as 'paraplegia'. Some early cases of 'paraplegia' have been described in sufficient detail to recognise a condition resembling what we now call multiple sclerosis and these cast an interesting light on the approach to therapy before the disease had a name. Multiple sclerosis was differentiated and 'framed' as a separate identifiable entity by von Frerichs, Vulpian, Charcot and others in the mid-nineteenth century. Once framed by its pathology, clinical picture, course and prognosis, cases were diagnosed by others around the world. As knowledge of the disease increased, theories of cause and approaches to treatment increased so that a review in 1935 covered 158 treatments used in MS. There were subsequent waves of therapies including anticoagulants, antibiotics, histamine desensitisation, various diets, vaccines and anti-cancer agents, as well as numerous claims of 'cures'. After the 1960s the methodology for carrying out randomised clinical trials became better defined, aided by improved disease classification and disability scales. As data accumulated, theories were tested to account for observations of genetic influences, environmental factors, geographical variations, infections and immunological changes. The development of multiple sclerosis societies advanced research and public education and changed attitudes towards the disease. At the same time, attitudes of physicians towards management of people with multiple sclerosis changed. In the last fifty years, the major advances have been in basic research to elucidate the mechanisms and processes underlying the disease, the development of imaging techniques (MRI) and the development of immunomodulatory drugs which, for the first time, are altering the outcome of the disease. We have now entered the therapeutic era of multiple sclerosis, with continual major advances bringing hope and benefit to people with multiple sclerosis.

Entities:  

Mesh:

Year:  2009        PMID: 19200863     DOI: 10.1016/S0022-510X(09)70003-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  23 in total

1.  Jean-Martin Charcot: the father of neurology.

Authors:  David R Kumar; Florence Aslinia; Steven H Yale; Joseph J Mazza
Journal:  Clin Med Res       Date:  2010-08-25

2.  "No performance in surgery more interesting and satisfactory": Harvey Cushing and his experience with spinal cord tumors at the Johns Hopkins Hospital.

Authors:  Hormuzdiyar H Dasenbrock; Courtney Pendleton; Aaron A Cohen-Gadol; Jean-Paul Wolinsky; Ziya L Gokaslan; Alfredo Quinones-Hinojosa; Ali Bydon
Journal:  J Neurosurg Spine       Date:  2011-01-21

3.  Identifying strains that contribute to complex diseases through the study of microbial inheritance.

Authors:  Jeremiah J Faith; Jean-Frédéric Colombel; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-09       Impact factor: 11.205

4.  VEP and PERG in patients with multiple sclerosis, with and without a history of optic neuritis.

Authors:  M Janáky; Á Jánossy; G Horváth; G Benedek; G Braunitzer
Journal:  Doc Ophthalmol       Date:  2017-04-18       Impact factor: 2.379

5.  Friedrich Theodor von Frerichs (1819-1885).

Authors:  Julia Thormann; Holger Steinberg
Journal:  J Neurol       Date:  2013-03-20       Impact factor: 4.849

6.  Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?

Authors:  Vladimir V Bamm; George Harauz
Journal:  Cell Mol Life Sci       Date:  2014-02-07       Impact factor: 9.261

7.  Protective and detrimental roles for regulatory T cells in a viral model for multiple sclerosis.

Authors:  Nicholas E Martinez; Fridrik Karlsson; Fumitaka Sato; Eiichiro Kawai; Seiichi Omura; Alireza Minagar; Matthew B Grisham; Ikuo Tsunoda
Journal:  Brain Pathol       Date:  2014-02-25       Impact factor: 6.508

8.  Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis.

Authors:  Nicholas E Martinez; Fumitaka Sato; Eiichiro Kawai; Seiichi Omura; Robert P Chervenak; Ikuo Tsunoda
Journal:  Future Virol       Date:  2012-06       Impact factor: 1.831

9.  Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis.

Authors:  Mansoureh Togha; Mehrdad Jahanshahi; Leila Alizadeh; Soodeh Razeghi Jahromi; Gelareh Vakilzadeh; Bahram Alipour; Ali Gorji; Amir Ghaemi
Journal:  Mol Neurobiol       Date:  2016-03-12       Impact factor: 5.590

Review 10.  Is multiple sclerosis a mitochondrial disease?

Authors:  Peizhong Mao; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.